Get the Stockscreener App
151.95
6.53%
-10.62
Natera Inc stock is traded at $151.95, with a volume of 4.39M.
It is down -6.53% in the last 24 hours and down -0.01% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$162.57
Open:
$164.75
24h Volume:
4.39M
Relative Volume:
2.68
Market Cap:
$21.30B
Revenue:
$1.53B
Net Income/Loss:
$-214.69M
P/E Ratio:
-86.34
EPS:
-1.76
Net Cash Flow:
$-43.68M
1W Performance:
-3.01%
1M Performance:
-0.01%
6M Performance:
+13.30%
1Y Performance:
+59.03%
1-Day Range:
$147.63
$166.00
1-Week Range:
$147.63
$166.00
52-Week Range:
$92.14
$183.00
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
151.95 | 21.30B | 1.53B | -214.69M | -43.68M | -1.76 |
|
TMO
Thermo Fisher Scientific Inc
|
403.13 | 159.89B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.73 | 142.45B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
491.70 | 37.95B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
106.93 | 30.97B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
148.99 | 26.72B | 15.50B | 1.33B | 2.16B | 7.34 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-08-24 | Resumed | Craig Hallum | Buy |
| Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-05-23 | Initiated | UBS | Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Mar-08-22 | Initiated | Goldman | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Sep-28-20 | Initiated | Morgan Stanley | Overweight |
| Sep-17-20 | Initiated | SVB Leerink | Outperform |
| Jun-10-20 | Resumed | Piper Sandler | Overweight |
| May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-05-18 | Initiated | JP Morgan | Neutral |
| Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
| Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-10-16 | Reiterated | The Benchmark Company | Buy |
| May-23-16 | Reiterated | The Benchmark Company | Buy |
| May-11-16 | Reiterated | The Benchmark Company | Buy |
| Apr-19-16 | Initiated | The Benchmark Company | Buy |
| Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-04-15 | Initiated | Robert W. Baird | Outperform |
| Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-27-15 | Initiated | Piper Jaffray | Overweight |
| Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
Natera, Inc. (NASDAQ:NTRA) Q1 2025 Earnings Call Transcript - Insider Monkey
UBS Raises Natera (NTRA) Price Target to $218, Maintains Buy Rat - GuruFocus
Natera’s Strong Performance and Growth Potential Justifies Buy Rating - TipRanks
Natera Inc. Shines in Earnings Call with Strong Growth - TipRanks
Cathie Wood’s ARK buys Shopify, Illumina stock; sells Palantir, Natera - Investing.com
RBC maintains Outperform on Natera stock, price target at $251 - Investing.com
Natera stock price target raised to $200 at TD Cowen - Investing.com
RBC maintains Outperform on Natera stock, price target at $251 By Investing.com - Investing.com India
NTRA: Barclays Raises Price Target for Natera | NTRA Stock News - GuruFocus
NTRA: TD Cowen Increases Price Target on Strong Performance | NTRA Stock News - GuruFocus
8 Analysts Have This To Say About Natera - Benzinga
NTRA Price Target Increased as Natera Achieves Record Growth | NTRA Stock News - GuruFocus
NTRA Stock Sees Price Target Increase by Barclays to $190 | NTRA Stock News - GuruFocus
Natera Q1 2025 slides: 37% revenue growth drives raised guidance By Investing.com - Investing.com Nigeria
Natera, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
Natera Inc (NTRA) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Raised Guidance - Yahoo Finance
Natera Inc. Reports Strong Q1 2025 Financial Growth - TipRanks
Natera Inc earnings beat by $0.14, revenue topped estimates - Investing.com
Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Natera (NTRA) Reports Strong Q1 2025 Growth and Raises Revenue Guidance - GuruFocus
Natera Q1 2025 Earnings Call Transcript - MarketBeat
Natera (NASDAQ:NTRA) Surprises With Strong Q1, Guides for Strong Full-Year Sales - Yahoo Finance
Earnings call transcript: Natera Q1 2025 beats EPS forecast, stock rises - Investing.com UK
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Natera Inc reports results for the quarter ended March 31Earnings Summary - TradingView
NTRA Reports Strong Q1 Revenue Exceeding Expectations | NTRA Stock News - GuruFocus
Natera Q1 2025 slides: 37% revenue growth drives raised guidance - Investing.com
Natera Q1 Net Loss Narrows, Revenue Rises; Increases Full Year Revenue Outlook - marketscreener.com
Natera: Q1 Earnings Snapshot - marketscreener.com
Natera Inc (NTRA) Q1 2025 Earnings: EPS of ($0.50) Beats Estimate, Revenue Surges to $501.8 Million, Exceeding Expectations - GuruFocus
Natera Reports First Quarter 2025 Financial Results - Yahoo Finance
Natera (NTRA) to Present Significant Breast Cancer Data at 2025 ESMO Congress | NTRA Stock News - GuruFocus
Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress | NTRA Stock News - GuruFocus
Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress - Stock Titan
Natera Inc (NTRA) Q1 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Cathie Wood’s ARK Makes Bold Tuesday Moves with Key Stock Swaps - Wall Street Pit
Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows - BioSpace
What To Expect From Natera’s (NTRA) Q1 Earnings - Yahoo Finance
Natera reports outcomes from study of MRD test for soft tissue and bone sarcomas - Medical Device Network
Natera (NTRA) Highlights Promising Study Results for Sarcoma Det - GuruFocus
Natera (NTRA) Highlights Promising Study Results for Sarcoma Detection | NTRA Stock News - GuruFocus
Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera | NTRA Stock News - GuruFocus
Breakthrough: Largest-Ever Sarcoma Study Validates Natera's Cancer Detection Test with 93% Accuracy - Stock Titan
Learn to Evaluate (NTRA) using the Charts - news.stocktradersdaily.com
CLASS ACTION: Kessler Topaz Meltzer & Check, LLP Reminds Natera, Inc. Shareholders of Securities Fraud Class Action Lawsuit and Encourages Investors with Losses over $250,000 to Contact the Firm - Newsfile
Notice to Shareholders of Natera, Inc. (NTRA) Regarding Dismissal of Putative Investor Class Action - TradingView
Natera to Report its First Quarter Results on May 8, 2025 - BioSpace
Natera’s chief legal officer sells $303,299 in stock By Investing.com - Investing.com South Africa
Natera executive chairman sells shares for $261,449 By Investing.com - Investing.com Canada
Natera president Solomon Moshkevich sells $335,714 in stock By Investing.com - Investing.com South Africa
Natera executive chairman sells shares for $261,449 - Investing.com Australia
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.94%
0.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):